RxDoctor Payments Data

Paul Kim, DPM

Foot & Ankle Surgery · Dallas, TXNPI 1013971027

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (43.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by KCI USA, Inc. at 50.1% of the total. Among foot & ankle surgery clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$927,873in general payments, 2019–2025

Across 649 payments — averaging $1429.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • KCI USA, Inc.$465K
  • Polynovo North America LLC$220K
  • Solventum Corporation$111K
  • Smith+Nephew$48K
  • Urgo Medical North America, LLC$30K
  • Integra Lifesciences Corporation$20K
  • plus $33K from 13 others
$44,118in research payments, 2019–2025

Across 5 payments — averaging $8823.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • KCI USA, Inc.$32K
  • Smith+Nephew$12K

What the payments were for

  • Consulting fees$405,43444%
  • Speaking & faculty fees$380,09941%
  • Grants$2,5000%
  • Travel & lodging$107,81212%
  • Food & beverage$15,3232%
  • Education$16,7042%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$927,873 in reported general payments places this provider in the 95th percentile of 684 foot & ankle surgery providers in Texas.

See all foot & ankle surgery providers in Texas

Medicare billing

Part B allowed, 2024
$61,034
Medicare patients
131
Services billed
604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav40$461
Doxycycline Monohydrate29$404
Ciprofloxacin Hcl27$260
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen24$185
Tramadol Hcl12$76

Paid to pharmacies, not to this prescriber.

Other foot & ankle surgery in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →